Project description:Analisis del transcriptoma de Myrciaria dubia "camu camu" con tecnologia de ultima generación: identificacion de genes y descripcion de vias metabolicas
Project description:Primary objectives: El objetivo principal del estudio es determinar el tiempo libre de progresión de la enfermedad en los pacientes ancianos sometidos al tratamiento de estudio
Primary endpoints: El parámetro principal de eficacia es tiempo libre de progresión, definido como el tiempo desde el inicio del tratamiento, hasta que se objetiva enfermedad progresiva según los criterios RECIST
Project description:Primary objectives: ? Determinar si el consumo de opiáceos en pacientes tratados con perfusión continua de anestésico local es inferior al consumo de pacientes tratados con perfusión contínua de suero fisiológico
Primary endpoints: 1. Reacción adversa grave a alguno de los fármacos administrados, según criterio clínico.2. Retirada accidental u oclusión de los catéteres3. Infección de la herida quirúrgica. 4. Insuficiencia hepática (aumento de transaminasas, aumento de la bilirrubina y alargamiento del tiempo de protrombina)
En caso de suspensión del estudio, la pauta analgésica a administrar estará constituida por:
? Cirugía de colon: Analgesia con PCA de Cloruro mórfico: bolus de 0,5mg, bloqueo de 5 min. i AINEs pautados? Cirugía hepática: Sistema de PCA : bolus 0,5 mg, bloqueo de 8 min i AINEs pautados.
Project description:Primary objectives: Evaluar la eficacia de Cabazitaxel en pacientes con cáncer colorrectal metastásico resistente al tratamiento estándar.
Primary endpoints: Evaluar la eficacia de Cabazitaxel mediante la estimación de la tasa de respuesta global (ORR), entendida como el porcentaje de individuos que alcanzan una respuesta tumoral completa (CR) o una respuesta tumoral parcial (PR) en cada brazo y a su vez comparándolos entre sí. Se llevarán a cabo evaluaciones del tumor hasta progresión o abandono del estudio. Para ello se utilizarán los criterios RECIST 1.1 cada 8 semanas.
Project description:Koolen-de Vries syndrome (KdVS) is a multi-system disorder characterized by intellectual disability, friendly behavior, and congenital malformations. The syndrome is caused either by microdeletions in the 17q21.31 chromosomal region or by variants in the KANSL1 gene. The reciprocal 17q21.31 microduplication syndrome is associated with psychomotor delay, and reduced social interaction. To investigate the pathophysiology of 17q21.31 microdeletion and microduplication syndromes, we generated three mouse models: 1) the deletion (Del/+); or 2) the reciprocal duplication (Dup/+) of the 17q21.31 syntenic region; and 3) a heterozygous Kansl1 (Kans1+/-) model. We found altered weight, general activity, social behaviors, object recognition, and fear conditioning memory associated with craniofacial and brain structural changes observed in both Del/+ and Dup/+ animals. By investigating hippocampus function, we showed synaptic transmission defects in Del/+ and Dup/+ mice. Mutant mice with a heterozygous loss-of-function mutation in Kansl1 displayed similar behavioral and anatomical phenotypes compared to Del/+ mice with the exception of sociability phenotypes. Genes controlling chromatin organization, synaptic transmission and neurogenesis were upregulated in the hippocampus of Del/+ and Kansl1+/- animals. Our results demonstrate the implication of KANSL1 in the manifestation of KdVS phenotypes and extend substantially our knowledge about biological processes affected by these mutations. Clear differences in social behavior and gene expression profiles between Del/+ and Kansl1+/- mice suggested potential roles of other genes affected by the 17q21.31 deletion. Together, these novel mouse models provide new genetic tools valuable for the development of therapeutic approaches.
Project description:Loss of chromosome 7 and del(7q) [-7/del(7q)] are recurring cytogenetic abnormalities in hematologic malignancies, including acute myeloid leukemia and therapy-related myeloid neoplasms, and associated with an adverse prognosis. We performed SNP array analysis on de novo and therapy-related myeloid neoplasms and identified a 2.17 Mb commonly deleted segment on chromosome band 7q22.1 containing CUX1, a gene encoding a homeodomain-containing transcription factor. Haploinsufficiency of the highly conserved ortholog, cut, led to hemocyte overgrowth and tumor formation in Drosophila melanogaster. Similarly, haploinsufficiency of CUX1 gave human hematopoietic cells a significant engraftment advantage upon transplantation into immunodeficient mice. These data identify CUX1 as a conserved, haploinsufficient tumor suppressor frequently deleted in myeloid neoplasms.